

# Children's acceptability of furosemide

<b>Submission date</b> 10/01/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/01/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 12/02/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This study aims to assess the acceptability of an orodispersible formulation of furosemide in children.

### Who can participate?

Children from birth up to their 12th birthday can participate. They have to be taking a whole mg dose of furosemide e.g. 2mg, not 2.3mg to be able to participate. They also need to be able to take the medicine orally i.e. not down a feeding tube.

### What does the study involve?

The study involves replacing the child's normal dose of furosemide (usually a liquid formulation) with the orodispersible formulation of furosemide. The dose will be the same. The only difference is the formulation of the medicine.

### What are the possible benefits and risks of participating?

A single-dose direct switch in the formulation used is likely to have very little impact on participants as the same dose/frequency of treatment which is clinically indicated will be given for one dose only as part of this acceptability study. The new formulation has also been shown to be bioequivalent (meaning the same dose is absorbed) to an existing licensed furosemide tablet in adults.

### Where is the study run from?

Alder Hey Children's NHS Foundation Trust, UK

### When is the study starting and how long is it expected to run for?

October 2023 to January 2025. The first patient was recruited on 18th June 2024 and recruitment is expected to run until the end of December 2024.

### Who is funding the study?

Proveca Ltd, UK

### Who is the main contact?

The chief investigator for the study is Dr Daniel Hawcutt, [d.hawcutt@liverpool.ac.uk](mailto:d.hawcutt@liverpool.ac.uk)

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Daniel Hawcutt

### Contact details

Alder Hey Children's NHS Foundation Trust, Eaton Road  
Liverpool  
United Kingdom  
L12 2AP  
+44 (0)151 252 5570  
dan.hawcutt@alderhey.nhs.uk

### Type(s)

Public, Scientific

### Contact name

Miss Maisie Stephenson

### Contact details

Proveca Ltd, WeWork, One St Peter's Square  
Manchester  
United Kingdom  
M2 3DE  
+44 (0) 161 468 2627  
maisiestephenson@proveca.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

339343

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

PRO/FUR/002, CPMS 60685

## Study information

### Scientific Title

Acceptability of age-appropriate furosemide orodispersible tablets (ODTs) in the paediatric population

**Acronym**  
CHAFfinch

**Study objectives**

To assess the acceptability of a new formulation of furosemide for children.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 15/04/2024, West Midlands - South Birmingham Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8019; southbirmingham.rec@hra.nhs.uk), ref: 24/WM/0055

**Study design**

Single-centre palatability and acceptability observational study

**Primary study design**

Observational

**Study type(s)**

Other

**Health condition(s) or problem(s) studied**

All patients taking oral furosemide and meeting the inclusion and exclusion criteria will be considered.

**Interventions**

This study investigates a single replacement dose exposure of an orodispersible tablet formulation of furosemide (dose given as per current prescription).

The clinical team will identify participants taking oral furosemide. The research staff are informed of potential participants and discuss the study with them and/or their parents. Assent /consent is taken. The participant is then given the orodispersible furosemide product (same dose) and is filmed taking this so that researchers can review the video afterwards to score the palatability of the medicine. The participant and/or parents/carer are also asked to complete a questionnaire on the acceptability of the medicine. The total study duration is expected to be less than 30 minutes. There is no follow-up for this study.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Furosemide

**Primary outcome(s)**

Acceptability is measured with an adapted version of the composite endpoint using a score for swallowability at the time the participant takes the furosemide and a score for palatability performed by two researchers reviewing the videos that were taken of the participant taking the replacement dose

### **Key secondary outcome(s)**

The number of participants willing to take the orodispersible tablet formulation of furosemide in the future was measured using the following questions in participant or parent/carer questionnaires after the dose is given:

Overall, how happy would you be to take this new medicine in the future?

Would you be happy to give your child this new medicine in the future?

### **Completion date**

15/01/2025

## **Eligibility**

### **Key inclusion criteria**

1. Participants aged from birth (including pre-term neonates) to less than 12 years old (i.e up to their 12th birthday).
2. No limitation of nationalities, demographics, socio-economic or ethnic groups.
3. Written informed consent must be obtained from the child's parent / carer with parental responsibility.
4. Consent needs to be sought from a legal guardian who has an appropriate understanding of written English. If this is not possible, an interpreter will be sought. Parents/carers must however have the capacity to be able to understand the study information.
5. Written assent will be sought for all study participants aged 6 years and over, where appropriate. Ability to assent will be judged on a case-by-case basis by the research team.
6. The participant (inpatient or outpatient) is currently taking an oral formulation of furosemide and has completed at least 48 hours of oral treatment, with no dose alterations planned.
7. The participant (in agreement with their legal guardian) is willing to be video recorded while the study medication is administered.
8. The clinical team and/or the participant's parent / carer raise no concerns about the child's involvement in this study.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

0 days

### **Upper age limit**

11 years

**Sex**

All

**Total final enrolment**

10

**Key exclusion criteria**

1. Participants aged 12 years and older.
2. Participant(s) whose parent/guardian is unable to read and/or understand the study information sheet provided.
3. Child participant refuses to provide verbal assent to take part in the study, where appropriate.
4. Parent/carer unable or unwilling to give informed consent.
5. The participant has a known swallowing difficulty (with either solid or liquids).
6. The treating clinical team feel the participants' current prescribed dose of furosemide may need to change imminently i.e. their furosemide dose is too unstable/variable at present.
7. Participant is receiving their dose of oral furosemide via any type of enteral feeding tube such as nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG).
8. The child has a known allergy (or intolerance) to furosemide or any of the excipients included within the new ODT furosemide formulation.
9. The treating clinical team feel there are family or social issues (e.g. pronounced family distress or child protection intervention) that would make it inappropriate to approach the family to take part in the study.

**Date of first enrolment**

18/06/2024

**Date of final enrolment**

10/12/2024

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Alder Hey Children's NHS Foundation Trust

Eaton Road

Liverpool

United Kingdom

L12 2AP

**Sponsor information**

**Organisation**

Proveca (United Kingdom)

**ROR**

<https://ror.org/0090bh305>

**Funder(s)****Funder type**

Industry

**Funder Name**

Proveca Ltd

**Results and Publications****Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are not expected to be made available due to the full datasets being commercially sensitive and potentially used to support marketing authorisation applications.

**IPD sharing plan summary**

Not expected to be made available

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes